This study describes Lombardy's population-based colorectal cancer screening programme, using biennial faecal immunochemical tests, from 2006 to 2023. Data came from eight Health Protection Agencies, and incidence was estimated from hospital discharge records. Invitation coverage stayed above 90% in most biennial rounds, and participation averaged 45-50% before the pandemic and 42% after. Test positivity was 4-5%, with about 1000 cancers detected per biennium, and advanced adenoma detection fell over time. Cost per screened participant was €10-12, and adjusted incidence fell from 68.8 to 38.2 per 100,000 over 2007-2023. The design is observational, so the fall in incidence cannot be attributed to screening alone.
Why it is interesting: Two decades of routine data show how a faecal immunochemical test programme performs at regional scale. Participation stayed below half of those invited, yet recorded incidence fell by more than 40% over the same period.
Abstract — the authors' own words, CC BY
Objectives
Colorectal cancer (CRC) is one of the most common malignancies worldwide. Since 2006, the Lombardy Region has implemented a population-based CRC screening programme with biennial faecal immunochemical test. This study describes twenty years of programme performance, impact on CRC burden and associated costs. Study design
Population-based longitudinal observational study. Methods
We analysed 2006-2023 data, collected from the eight Health Protection Agencies in Lombardy and validated at regional and national levels. Key performance indicators were computed following national standards. Screening programme costs were derived from regional health budgets (2021-2024) and CRC incidence was estimated from hospital discharge data for 2002-2023. Results
Invitation coverage remained above 90% across most biennial screening rounds, with participation rates averaging 45-50% before the SARS-CoV-2 pandemic and recovering to 42% afterward. Positivity rates ranged from 4% to 5%, with approximately 1000 cancers detected per biennium. Detection rates for advanced adenomas decreased over time, while low-risk adenomas increased. The average cost per screened participant ranged from €10 to €12. Adjusted CRC incidence declined from 68.8 per 100,000 in 2007 to 38.2 in 2023. Conclusions
The programme has maintained high invitation coverage and sustained screening activity over two decades, with a substantial reduction in observed CRC incidence over the same period. Persistent participation and equity gaps highlight opportunities for further improvement.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.